SoftBank Group’s Recursion Pharmaceuticals RXRX Stock Holding History

SoftBank Group’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$50M	Hold	13,636,515	–	–	0.28%	15
2026 Q1	$41.9M	Hold	13,636,515	–	–	0.37%	14
2025 Q4	$55.8M	Sell	13,636,515 -1,030,976	-7%	-$5.11M	0.36%	15
2025 Q3	$71.6M	Hold	14,667,491	–	–	0.28%	16
2025 Q2	$74.2M	Hold	14,667,491	–	–	0.3%	15
2025 Q1	$77.6M	Hold	14,667,491	–	–	0.26%	12
2024 Q4	$99.2M	Buy	+14,667,491	New	+$98.6M	0.42%	10

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

SoftBank Group's RXRX Position: Q2 2026 in Review

SoftBank Group held its Recursion Pharmaceuticals (RXRX) position steady in Q2 2026 at 13,636,515 shares worth $50M. The position accounts for 0.28% of the portfolio, ranked #15.

SoftBank Group first reported a position in RXRX in Q4 2024 and has held it in 7 quarters since. The position peaked at $99.2M in Q4 2024. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

SoftBank Group held 13,636,515 shares of Recursion Pharmaceuticals worth $50M as of Q2 2026.
SoftBank Group left its Recursion Pharmaceuticals share count unchanged in Q2 2026.
Recursion Pharmaceuticals made up 0.28% of SoftBank Group's portfolio in Q2 2026, its #15 holding.
SoftBank Group first reported a position in Recursion Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
SoftBank Group's Recursion Pharmaceuticals position peaked at $99.2M in Q4 2024.
342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on SoftBank Group's 13F filing for Q2 2026, filed 14 Aug 2026.